Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial ULTRA-V (Ublituximab with Umbralisib ± Venetoclax) in CLL/SLL has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Ublituximab (ublituximab)
• Venetoclax (venetoclax)
• umbralisib

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2024-04-19